“Our employees have coped excellently with the second pandemic year and all its challenges. Despite strained supply chains, we were able to support our customers in their demanding projects in the development and production of biopharmaceuticals and vaccines, grew strongly, and achieved, and partly exceeded, our financial targets that were raised several times during the year. We have also made excellent progress in the expansion of our production capacities. I am especially pleased that we were able to create more than 2,800 additional jobs.

We are very optimistic about our future business development. Following the jump in profitability in 2021, we are aiming at achieving a similar high level of profitability in the current fiscal year. We have also set ourselves an ambitious target to continuously reduce our CO₂ emission intensity.”

Chairman’s Message